Neuralstem's ALS Clinical Trial Progress, plus Caraco Pharmaceutical Laboratories is going private Print E-mail
By BioMedReports.com Staff   
Tuesday, 14 June 2011 19:24
Below is a look at some of the headlines for companies that made news in the healthcare sector on June 14, 2011.

Neuralstem, Inc. (AMEX:CUR), updated the progress of its ongoing Phase I human clinical trial of the Company's spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

After reviewing the safety data from the first 12 patients, the Company announced that all of whom received injections in the lumbar region of the spine only, the trial's Safety Monitoring Board (SMB) has unanimously approved advancing the trial to transplantions in cervical region.

The next three patients, all of whom are ambulatory, will each receive five injections, unilaterally, in the cervical spinal cord. The FDA must also approve the trial's moving to the next level of transplantations. The Company expects to present the data from the first twelve patients to the FDA in the near future.

The Phase I trial to evaluate the safety of Neuralstem's spinal cord stem cells in the treatment of ALS, the first FDA-approved ALS stem cell trial, has been underway since January, 2010.

Caraco Pharmaceutical Laboratories Ltd. (NYSE: CPD) announced that at a special meeting of stockholders held on June 14, 2011, Caraco's stockholders voted to approve and adopt the previously announced merger agreement by and among Sun Pharmaceutical Industries Limited, Sun Pharma Global, Inc., Sun Laboratories, Inc. and Caraco
Caraco's common stock will be delisted from the NYSE Amex as of the close of trading on June 14, 2011 and deregistered under the Securities Exchange Act of 1934, as amended.


Also Tuesday:


Amarantus BioSciences, Inc. (OTCBB: AMBS), a California-based biotechnology company developing first-in-class proteins, today announced the successful completion of the Company's capital restructuring initiatives, including a 25-for-1 forward stock split (the "Forward Stock Split"), which was previously approved by its stockholders and announced on June 2, 2011.

BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that it has qualified for and been selected to join the Russell 2000® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 24, 2011, according to a preliminary list of additions posted June 10, 2011, available at www.russell.com/indexes.

Connectyx Technologies Holdings Group, Inc. (PINKSHEETS: CTYX) ("Connectyx"), www.connectyx.com, manufacturer and distributor of the MedFlash®, the nation's premier Personal Health and Wellness Management System (ePHM) for maintaining personal health records (PHR), announced today that the company will be advertising MedFlash in concert with MASA Assist in an upcoming USA TODAY Travel Guide.

CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the Company will participate in the Wells Fargo Securities 2011 Healthcare Conference on Thursday, June 23, 2011 at 8:00 AM Eastern time, at the InterContinental Hotel in Boston.

Easton Pharmaceuticals Inc (OTC:EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, today announced that Mr. John Easton has been appointed to the position of CEO on an interim basis, enabling the Company's smooth transition from an early-stage research and development company to a commercial, revenue-producing specialty pharmaceutical company.

eHealth, Inc. (NASDAQ: EHTH), the nation's leading online source of health insurance for individuals, families and small businesses, today announced that its Board of Directors has approved a stock repurchase program authorizing the Company to purchase up to $30 million of its common stock.

EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that updated weight loss data from clinical studies of the Company's VBLOC® vagal blocking therapy delivered via the Maestro® Rechargeable (RC) System will be presented at the 28th Annual Meeting of the American Society of Metabolic and Bariatric Surgeons (ASMBS), being held June 13-17 in Orlando, FL.

Esterline Corporation (NYSE: ESL), a leading specialty manufacturer serving the aerospace and defense markets, today announced the promotion of Alain Durand to Group Vice President.

EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced that updated weight loss data from clinical studies of the Company's VBLOC® vagal blocking therapy delivered via the Maestro® Rechargeable (RC) System will be presented at the 28th Annual Meeting of the American Society of Metabolic and Bariatric Surgeons (ASMBS), being held June 13-17 in Orlando, FL.

IntelGenx Corp. (TSX VENTURE:IGX) (OTCBB:IGXT) ("IntelGenx", or "the Company"), announced that the U.S. Food and Drug Administration ("FDA") has accepted the Company's resubmission of its antidepressant CPI-300 New Drug Application 505(b)(2) in response to the February 2010 Complete Response Letter ("CRL") as a complete, Class 2 response.

MELA Sciences (NASDAQ: MELA) today announced that it applauds the U.S. Food and Drug Administration's (FDA) renewed focus on preventing and treating melanoma, the deadliest form of skin cancer.

OncoSec Medical Inc. (OTCBB: ONCS), which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today two appointments to its clinical team who will lead the clinical operations of OncoSec's ElectroOncology therapies.

PAREXEL International Corporation (NASDAQ:PRXL) announced today that it will be presenting at the Wells Fargo Healthcare Conference in Boston, MA.

In an exclusive interview, Scott R. Silverman, Chairman and CEO of PositiveID Corporation (NASDAQ: PSID), speaks about some of his company's upcoming positive developments and addressed why he purchased more of his company's stock recently.

Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces the signing of an exclusive marketing agreement with PACE Claims Services LLC (PACE) to provide educational and marketing services on behalf of Rosetta Genomics' miRview® meso diagnostic test to defendants and insurers in mesothelioma legal cases worldwide.

Supertex (NASDAQ: SUPX), a recognized leader in high voltage analog and mixed signal integrated circuits (ICs), today introduced the MD1712, a two channel, five level, high voltage, high speed ultrasound transmitter driver IC, designed for portable medical diagnostic ultrasound imaging applications.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter